– The MINISTONE-2 study showed XOFLUZA, given as a new oral suspension, is a well-tolerated and effective potential treatment for the flu in otherwise healthy children aged one to less than 12 years – – Approximately one in three children develop the flu every year and they are often contagious longer than adults – treating children may therefore help reduce symptoms and prevent the spread of the flu to the wider community – SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Jul. 3, 2019– Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III MINISTONE-2 study met its primary endpoint, demonstrating that XOFLUZA™ (baloxavir marboxil) was well-tolerated in children with the flu. The study also showed that XOFLUZA is comparable to oseltamivir – a proven effective treatment for children with the flu – at reducing the duration of flu symptoms, including fever. The study assessed XOFLUZA versus ...
In phase 2b clinical trial work, FLU-v met its goal of boosting T-cell immune response at 42 days and 180 days after vaccination. The infection rate came down by meeting a secondary endpoint of boosting antibodies in vaccinated patients. Thus, this single adjuvant dose is considered as the "most immunological and efficient."
A research team from the University of Ottawa in Canada revealed a safe and inexpensive treatment by employing Viagra and flu vaccines that might stop cancer revival. Tadalafil (Cialis), sildenafil (Viagra) in combination with Agriflu were used in the research work.
In the pilot phase, individual grants would be provided which would range from $250,000 to $2 million over two years. An additional $10 million may be provided if project is promising in animal studies but that money won’t be the part of this funding round
GSK touted phase 3 data of its quadrivalent flu vaccine Fluarix Tetra. As a severe flu season continues to unfold in the U.S., GlaxoSmithKline is touting phase 3 study data showing its Fluarix Tetra can protect young children who are among the most vulnerable to the virus.
With its worldwide impact and mounting death toll, the 2017-2018 influenza season shows that the viral disease isn’t just a fever and the sniffles, but rather a dangerous disease that can spread rapidly between people. That’s why a leading healthcare technology company is pushing forward with trials that can help doctors and medical staff easily identify the disease early in the process through a simple breath test.
As the worst flu season in a decade rages on, a potentially groundbreaking new drug that can kill the flu virus in just one day has won regulatory approval—in Japan.
The flu is a bit of a stealth microbe. Infected people may shed significant amounts of flu virus simply by breathing, scientists have discovered.
It’s flu season, and many of us find ourselves glancing nervously at anyone coughing or sniffling in our vicinity. But how, besides shielding ourselves from public sneezers, do we avoid coming into contact with infections?
Even when the flu vaccine doesn't prevent disease, it can ease some of the consequences, researchers said here.
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.